IXICO

Nuanced screening scenarios for patients enrolling in AD clinical trials will be key to understanding disease progression and maximising the insight gained from the trial. Robin Wolz talks about the findings of our work at CTAD Clinical Trials on Alzheimer's Disease this week and the depth of knowledge gained from the Global Alzheimer's Platform Foundation Bio-Hermes Trial. Our CEO, Bram Goorden comments: "The excitement at this edition of CTAD is palpable with important reads-outs, including our own further Bio-Hermes analyses, but it is also clear that we will see many new AD programs starting in the near future. I look forward to IXICO playing a major role in assisting these efforts as we have enabled our platform to support the latest imaging biomarker requirements. Alzheimer’s research and development for patients is thriving!” To find out more about our work in utilising imaging biomarkers to support patient stratification, safety, and efficacy reporting, view the latest publications that we've presented over 2024: https://lnkd.in/dUd5nnT And if you're interested in learning more about Robin's presentation - drop us a message.

#IXI – the brains behind brain scans Know anyone who’s suffering from Alzheimer's (AD), Parkinson's (PD) &/or Huntington’s (HD)? These neurological conditions tragically affect 10ms of people worldwide. Luckily there’s help on its way. You see after several false starts, two Alzheimer's drugs were approved last year. Both treatments slow a patient’s cognitive decline, but require regular brain scans to monitor possible side-effects. These successes however have triggered an avalanche of new neurological research, reflecting the enormous unmet need. Here new clinical studies are being conducted on next generation therapeutics. Most of which also need MRIs in order to assess a drug’s safety, efficacy & longitudinal performance, as well as to assist in patient trial selection. This is where IXICO (Mrkcap £9m) fits in. It is one of the world’s leaders in the highly specialised assessment of brain scans. Helping BigPharma & CROs develop new drugs right from the test-tube, through to commercial launch (see charts) & post marketing surveillance. The firm is currently running 26 trials for 18 customers. Here its cutting edge science, industry experts & AI algorithms can detect & interpret >150 unique brain structures & digital biomarkers with microscopic precision. In fact, its highly contextualised database, incorporating a vast repository of 250k images, acts as a major competitive moat. All the information is securely stored too for the client within IXICO’s end-to-end TrialTracker software platform. Thus improving efficiency, speed, regulatory submissions and quality of decision making. Sure the past 2-3 years has been tough across the whole sector, as many Biotechs have dialled back investment. Yet equally this is changing, with the Board aiming to almost double turnover to £10m over the next 3-4 years vs an est £5.5m for Sept FY24. Breakeven sales is c.£8m. Whilst the orderbook stood at a healthy £15.1m on 31 Aug’24 vs £12.7m Mar'24. This strong growth will be achieved by leveraging its renowned HD expertise (£12m TAM) to penetrate further into the much larger research pools of AD (£30m) & PD (£15m). Alongside expanding more into the US and incorporating new digital biomarkers into the imaging platform. All funded after the recent over-subscribed £4.05m placing at 9.5p. Lastly wrt the numbers, house broker Cavendish have a 24p/share price target, based on Sept FY’25 sales & EBITDA coming in at £6.0m & -£1.4m respectively. Plus at 9.5p, the stock trades on <1x EV/revs, which looks far too cheap. CEO Bram Goorden – who joined in the summer & has been pivotal in driving IXICO’s expansion strategy - commented: "The fundraising will accelerate the growth & commercial reach of our AI driven technology platform.” Similarly, CSO Robin Wolz has been invited to present at several prominent industry events. An encouraging sign of the increasing importance of #IXI's specialist imaging services. Disclosure: IXICO is a Vox Markets client

We've had a fantastic few days at CTAD Clinical Trials on Alzheimer's Disease 2024 in Madrid, Spain! Thank you to everyone that's spoken with Robin Wolz, Bram Goorden and Roxanne Langlois during the conference, we are still around so if you have a moment, please do say hello! Here's a photo of Robin as he delivers his presentation titled: "A multi-stage approach to screen Amyloid status using plasma p-Tau217 prior to confirmatory Imaging applied to the Bio-Hermes Trial" where we hope insights from the Global Alzheimer's Platform Foundation Bio-Hermes Trial will help inform the AD clinical research community. 🎃Enjoy the spooky festivities today, and if you're at CTAD, we hope to see see you there 🎃

Next week, we are at CTAD Clinical Trials on Alzheimer's Disease 2024 in Madrid, Spain from Oct 29th to Nov 1st! Here's a recap of our presence: Robin Wolz will present our latest findings with the Global Alzheimer's Platform Foundation on the Bio-Hermes Trial. 🕛Thursday, October 31st 2024 at 2:35pm in OC26 🧠 Oral Communication "A multi-stage approach to screen Amyloid status using plasma p-Tau217 prior to confirmatory Imaging applied to the Bio-Hermes Trial" If you're at CTAD, Bram Goorden and Roxanne Langlois will be with Robin to discuss and share imaging biomarker insights with the AD research community. Drop us a message if you're going so we can arrange a meeting! See you in Madrid!

Innovative trial recruitment strategies are crucial as it’s estimated that by 2050, 153 million people will live with dementia. Our deep-learning framework for clinical trial enrichment in Alzheimer’s Disease enhances trial enrichment using neuroimaging and clinical/demographic variables, designed to handle missing inputs effectively. 🧠 We utilized T1-MR and amyloid-PET images from major repositories and trained advanced neural networks and classifiers. This approach has shown promising results in identifying participants at early disease stages with accelerated decline. Our framework achieved high accuracy and can significantly reduce PET imaging costs. To learn more about our methods and results, download the full poster 📄https://lnkd.in/e9mRMRXW

In the ongoing quest to understand Alzheimer’s disease, recent studies have highlighted the importance of examining racial differences in amyloid PET imaging. Our latest research from the Global Alzheimer's Platform Foundation Bio-Hermes study compares amyloid positivity and global cortical SUVR between Black and White non-Hispanic participants, aiming to shed light on these critical differences. Key Points: Accurate Monitoring: This study is crucial for precisely tracking amyloid positivity and understanding its implications across different racial groups. 📊 Central Visual Read: Visual read was performed centrally using the VisQ process in MIM Software, considering visual inspection and global cortical area SUVR for classification into Aβ+ or Aβ-. 🧠💻 Variation Noted: A significantly higher variation between SUVR cut-off and visual read in Aβ- Black participants compared to White participants was noted, suggesting potential differences in amyloid uptake patterns. 🎯 This research represents a significant step forward in understanding racial differences in amyloid uptake, offering new insights for better patient care and more effective treatment strategies. Future work will focus on regional SUVR analysis to further explore these findings. 🌟🧠 Interested in learning more? 📄 Download our detailed poster here: https://lnkd.in/emPust9G

Recent advancements in MS research have led to the development of a fully automatic method for detecting and quantifying white matter lesions using deep learning. This method, developed by IXICO’s imaging and biomarker science team, is crucial for accurately tracking disease progression and evaluating treatment efficacy in Multiple Sclerosis. Key points include: Accurate Monitoring: This method is essential for precisely tracking how the disease progresses and assessing the effectiveness of treatments. 📊 Advanced Deep Learning Models: The approach leverages sophisticated models like VoxelMorph and LG-Net, which have been retrained on extensive MRI datasets. 🧠💻 High Accuracy: It outperforms traditional methods, precisely detecting and quantifying new lesions. 🎯 This advancement represents a significant step forward in MS research, offering new possibilities for better patient care and more effective treatment strategies. Presented at ECTRIMS 2024. 🌟🧠 Interested in learning more? 📄 Download our detailed poster on this method here: https://lnkd.in/ebWG9xSy

We're attending CTAD Clinical Trials on Alzheimer's Disease 2024 in Madrid, Spain from Oct 29th to Nov 1st! Robin Wolz will present our latest findings with Global Alzheimer's Platform Foundation on the Bio-Hermes Trial. 🕛Thursday, October 31st 2024 at 2:35pm in OC26 🧠 Oral Communication "A multi-stage approach to screen Amyloid status using plasma p-Tau217 prior to confirmatory Imaging applied to the Bio-Hermes Trial" Bram Goorden and Roxanne Langlois will be with Robin to discuss and share imaging biomarker insights with the AD research community. If you're going to CTAD, drop us a message to let us know you're going so we can arrange a meeting! See you in Madrid!

We’re #hiring a new Associate Image Analyst (6-month FTC) in Greater London, England. Apply today or share this post with your network.

This week, from September 18-20th, we will attend ECTRIMS in Copenhagen, Denmark! Here's a refresher of who's attending from IXICO: Kirsi Kinnunen will be presenting a poster on our latest work in understanding multiple sclerosis progression: 🕛 Poster Session 2 Session Date: Thursday, 19 September 2024 Session Time: 16.45 – 18.45 CEST 🧠 Poster P904 - Fully automatic detection and quantification of new white matter lesions using deep learning She will be at ECTRIMS to share imaging biomarker insights and learn from others in the MS clinical research field. Drop us a message if you're going to ECTRIMS! Maybe we can schedule a time to talk! See you in Copenhagen!